Ask an answerable question (PICO)：
Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, is administered weekly to manage body weight in diabetic patients. Yet, its efficacy in inducing weight loss among non-diabetic individuals remains to be established. This prompts the clinical inquiry: "Does semaglutide contribute to weight reduction in obese patients who do not have diabetes?"
The Method and Analysis of Literature Review：
In addressing the clinical question posited, we formulated a PICO framework and undertook an exhaustive literature search across PubMed, Embase, the Cochrane Library, and the CEPS Airiti Chinese Electronic Database. Subsequently, we meticulously identified and selected systematic reviews and meta-analyses that aligned with our defined topic and PICO criteria. The assessment of the literature's quality was rigorously conducted using the Critical Appraisal Skills Programme (CASP), ensuring a thorough evaluation of the evidence. Furthermore, we executed an evidence grading assessment utilizing the evidence classification standards set by the Oxford University Centre for Evidence-Based Medicine, in conjunction with the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) evidence grading system. This comprehensive approach allowed us to evaluate and classify the evidence meticulously, facilitating a structured and nuanced analysis of the literature in question.
Critical Appraisal：
The final selection process yielded two systematic reviews and meta-analyses of randomized clinical trials, which were subjected to a rigorous quality appraisal using the Critical Appraisal Skills Programme (CASP) to assess their credibility, relevance, and clinical applicability. According to the evidence classification standards of the Oxford University Centre for Evidence-Based Medicine, they were deemed Level 1 evidence. The GRADE system was applied, categorizing the study by Arastu et al. (2022) as moderate quality of evidence, and the study by Tan et al. (2022) as high quality of evidence. The research outcomes indicate that semaglutide significantly reduces body weight, waist circumference, and Body Mass Index (BMI) in obese patients who do not suffer from diabetes.
Results, Conclusions and Recommendations：
In non-diabetic patients, the administration of Semaglutide has been significantly associated with reductions in body weight, waist circumference, and Body Mass Index. The once-weekly dosing regimen of Semaglutide enhances medication adherence when compared to daily dosing, presenting a notable advancement for patients with historically poor adherence. However, as a relatively novel approach to weight reduction, the long-term impact of Semaglutide on chronic obesity necessitates further validation through extended research and an increased number of randomized clinical trials (RCTs).
王柏權 王柏予*
